Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis?

Clinical Infectious Diseases

Volumn 58, Issue 4, 2014, Pages

  Gardiner, B J ^a   Mahony, A A ^a   Ellis, A G ^a   Lawrentschuk, N ^b,c   Bolton, D M ^b   Zeglinski, P T ^a   Frauman, A G ^a,b   Grayson, M L ^a,b  

^a AUSTIN HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

fosfomycin; infection; prostate; prostatectomy; urology

Indexed keywords

FOSFOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG PENETRATION; DRUG TISSUE LEVEL; DRUG URINE LEVEL; ESTIMATED GLOMERULUS FILTRATION RATE; GLOMERULUS FILTRATION RATE; GRAM NEGATIVE INFECTION; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MALE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT GRAM NEGATIVE BACTERIAL INFECTION OF THE PROSTATE; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; PROSTATITIS; TANDEM MASS SPECTROMETRY; TRANSRECTAL ULTRASONOGRAPHY; TRANSURETHRAL RESECTION; URINALYSIS; VERY ELDERLY; CHEMISTRY; GRAM-NEGATIVE BACTERIAL INFECTIONS; ORAL DRUG ADMINISTRATION; PROSTATE; SERUM; URINE;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, LIQUID; FOSFOMYCIN; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE; PROSTATITIS; SERUM; TANDEM MASS SPECTROMETRY; URINE;

EID: 84893256345     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit704     Document Type: Article

References (19)

1. Prakash V, Lewis JS II, Herrera ML,Wickes BL, Jorgensen JH. Oral and parenteral therapeutic options for outpatient urinary infections caused by Enterobacteriaceae producing CTX-M extended-spectrum β-lactamases. Antimicrob Agents Chemother 2009; 35:1278-80.
2. Davidson AJ, Webb DR, Lawrentschuk N, Jennens ID, Sutherland M. Multi-resistant Escherichia coli sepsis following transrectal ultrasoundguided prostate biopsy. Br J Hosp Med (Lond) 2006; 67:98-9.
3. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268-81.
4. Williamson DA, Barrett LK, Rogers BA, Freeman JT, Hadway P, Paterson DL. Infectious complications following transrectal ultrasoundguided prostate biopsy: new challenges in the era of multidrug-resistant Escherichia coli. Clin Infect Dis 2013; 57:267-74.
5. Lipsy BA, Byren I, Hoey CT. Treatment of bacterial prostatitis. Clin Infect Dis 2010; 50:1641-52.
6. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extendedspectrum beta-lactamase producing Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010; 10:43-50.
7. Oteo J, Bautista V, Lara N, et al. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum betalactamase (ESBL)-producing Escherichia coli. J Antimicrob Chemother 2010; 65:2459-63.
8. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52:e103-20.
9. Frimodt-Moller N. Fosfomycin. In: Grayson ML, Crowe SM, McCarthy JS, et al., eds. Kucers' the user of antibiotics. 6th ed. London: Edward Arnold (Publishers) Ltd, 2010.
10. Takasaki N, Ra S, Okada S, et al. Transference of antibiotics into prostatitic tissues: sampling method by transurethral resection for the measurement of concentration of antibiotics in the prostatic tissues [in Japanese]. Hinyokika Kiyo 1986; 32:969-75.
11. Yang JC, Tang J, Li Y, Fei X, Shi H. Contrast-enhanced transrectal ultrasound for assessing vascularisation of hypoechoic BPH nodules in the transition and peripheral zones: comparison with pathological examination. Ultrasound Med Biol 2008; 34:1758-64.
12. Li L, Chen X, Dai X, Chen H, Zhong D. Rapid and selective liquid chromatographic/tandem mass spectrometric method for the determination of fosfomycin in human plasma. J Chromatogr B Analyt Technolol Biomed Life Sci 2007; 856:171-77.
13. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 22nd informational supplement. Wayne PA: CLSI 2012; 32.
14. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Available at: http://www.eucast.org/mic-distributions/. Accessed 1 October 2013.
15. Baert L, Billiet I, Vandepitte J. Prophylactic chemotherapy with fosfomycin trometamol versus placebo during transurethral prostate resection. Infection 1990; 18:s103-6.
16. Selvaggi FP, Battaglia M, Grossi FS, Disabato G, Cormio L. Oral prophylaxis with fosfomycin trometamol in transurethral prostatectomy and urological maneuvers: literature review and personal experience. Infection 1992; 20:S321-4.
17. Ongun S, Aslan G, Avkan-Oquz V. The effectiveness of single-dose fosfomycin as antimicrobial prophylaxis for patients undergoing transrectal ultrasound-guided biopsy of the prostate. Urol Int 2012; 89:439-44.
18. Shresha NK, Amuh D, Goldman MP, Riebel WJ, Tomford JW. Treatment of a complicated vancomycin-resistant enterococcal urinary tract infection with fosfomycin. Infect Dis Clin Pract 2000; 9:368-71.
19. Pulcini C, Bush K, Craig WA, et al.; ESCMID Study Group for Antibiotic Policies. Forgotten antibiotics: an inventory in Europe, the United States, Canada, and Australia. Clin Infect Dis 2012; 54:268-74.